Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aytu Biopharma (AYTU) Accumulated Expenses (2016 - 2026)

Aytu Biopharma has reported Accumulated Expenses over the past 14 years, most recently at $40.2 million for Q4 2025.

  • Quarterly Accumulated Expenses rose 1.99% to $40.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.2 million through Dec 2025, up 1.99% year-over-year, with the annual reading at $3.1 million for FY2025, 91.79% down from the prior year.
  • Accumulated Expenses was $40.2 million for Q4 2025 at Aytu Biopharma, up from $36.7 million in the prior quarter.
  • Over five years, Accumulated Expenses peaked at $54.4 million in Q3 2021 and troughed at $3.1 million in Q2 2025.
  • The 5-year median for Accumulated Expenses is $39.4 million (2024), against an average of $31.3 million.
  • Year-over-year, Accumulated Expenses soared 2664.57% in 2021 and then plummeted 92.15% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $50.7 million in 2021, then crashed by 91.89% to $4.1 million in 2022, then soared by 956.28% to $43.4 million in 2023, then decreased by 9.31% to $39.4 million in 2024, then grew by 1.99% to $40.2 million in 2025.
  • Per Business Quant, the three most recent readings for AYTU's Accumulated Expenses are $40.2 million (Q4 2025), $36.7 million (Q3 2025), and $3.1 million (Q2 2025).